Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Atai Life Sciences N : to Participate in Upcoming September Investor Conferences

09/03/2021 | 06:00pm EST

BERLIN, Sept. 03, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in in the following upcoming investor conferences in September:

Presentation details can be found below:

  • H.C. Wainwright 23rd Annual Global Investment Conference
    Format: Presentation
    Date and Time: Monday, September 13th, 2021, 9:00 a.m. ET
  • Baader Investment Conference (BIC)
    Format: Presentation
    Date and Time: Tuesday, September 21st, 2021, 11:30 a.m. ET

The presentations and archived webcasts will also be accessible in the Events section of atai’s website.

About atai Life Sciences

atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. atai's business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal mental health disorders. atai's mission is to bridge the gap between what the mental healthcare system currently provides and what patients need. atai is headquartered in Berlin, with offices in New York and London. For more information, please visit www.atai.life.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors discussed under the caption “Risk Factors” in atai's prospectus pursuant to Rule 424(b) filed with the U.S. Securities and Exchange Commission (“SEC”) on June 21, 2021, as such factors may be updated from time to time in atai's other filings with the SEC. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.

Investor Contact:
Greg Weaver
atai – Chief Financial Officer
Email: greg.weaver@atai.life 

Media Contact:
Anne Donohoe
KCSA Strategic Communications
Phone: +1 (212) 896-1265
Email: atai@KCSA.com 

Primary Logo

Source: atai Life Sciences

2021 GlobeNewswire, Inc., source Press Releases

All news about ATAI LIFE SCIENCES N.V.
11/22HC Wainwright Adjusts Atai Life Sciences to $50 From $40, Reiterates Buy Rating
11/17Berenberg Bank Adjusts Atai Life Sciences' Price Target to $38 From $35, Maintains Buy ..
11/16RBC Trims Price Target on Atai Life Sciences to $17 From $19, Maintains Sector Perform ..
11/15ATAI LIFE SCIENCES N.V. Management's Discussion and Analysis of Financial Condition an..
11/15European ADRs Move Slightly Higher in Monday Trading
11/15ATAI Life Sciences' Q3 Loss Narrows
11/15ATAI LIFE SCIENCES N : Reports Third Quarter 2021 Financial Results and Corporate Update -..
11/15Atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update
11/11Roth Capital Starts Atai Life Sciences at Buy With $32 Price Target
11/05Atai Life Sciences to Participate in Upcoming November Investor Conferences
More news
Analyst Recommendations on ATAI LIFE SCIENCES N.V.
More recommendations
Financials (USD)
Sales 2021 18,4 M - -
Net income 2021 -118 M - -
Net cash 2021 407 M - -
P/E ratio 2021 -13,5x
Yield 2021 -
Capitalization 1 794 M 1 794 M -
EV / Sales 2021 75,3x
EV / Sales 2022 22 224x
Nbr of Employees 35
Free-Float 90,8%
Duration : Period :
Atai Life Sciences N.V. Technical Analysis Chart | ATAI | NL0015000DX5 | MarketScreener
Income Statement Evolution
Mean consensus BUY
Number of Analysts 13
Last Close Price 11,19 $
Average target price 30,33 $
Spread / Average Target 171%
EPS Revisions
Managers and Directors
Florian Brand Chief Executive Officer
Gregory L. Weaver Chief Financial Officer
Srinivas G. Rao Chief Scientific Officer
Rolando GutÝerrez-Esteinou Chief Medical Officer
Alexis Marc Joel Louis de Rosnay Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431